BioMarin's Drug Shows Major Growth Improvements in Kids During Late-Stage Trial

• Voxzogo increased annualized growth rate by 2.33 cm more than placebo after 52 weeks in the 80-patient study of children aged 3 to 17 years
• No treatments are currently approved by the FDA or European Medicines Agency for hypochondroplasia, a rare genetic skeletal disorder causing short-limbed dwarfism
• The drug was already approved in 2021 for achondroplasia (another form of dwarfism), and BioMarin will submit a supplemental U.S. application in Q3 followed by European filings

Summary

Key Development:

BioMarin Pharmaceutical announced positive results from a late-stage trial of Voxzogo for treating hypochondroplasia, a rare genetic skeletal disorder causing short stature in children. The drug met its primary endpoint, and the news drove the company's stock higher.

Trial Results:

• The 52-week study of 80 patients (ages 3-17) showed Voxzogo significantly increased annualized growth rates compared to placebo
• Treated patients grew an additional 2.33 cm versus placebo
• Secondary endpoints were also achieved, with significant improvements in standing height and arm span

Medical Context:

Hypochondroplasia is a rare genetic disorder affecting bone growth and leading to short-limbed dwarfism. Currently, no treatments are approved by the U.S. FDA or European Medicines Agency for this condition, representing an unmet medical need.

Regulatory Timeline:

BioMarin plans to submit a supplemental application to U.S. regulators in Q3 2024, followed by filings in Europe and other regions. Voxzogo already received FDA approval in 2021 for achondroplasia, a related form of dwarfism.

Market Implications:

The positive trial results strengthen BioMarin's rare disease portfolio and could expand Voxzogo's addressable market. With no competing approved therapies, the company is positioned to capture the entire hypochondroplasia treatment market upon regulatory approval. The successful trial outcome validates the drug's mechanism across multiple growth disorders, potentially supporting premium pricing and strong uptake among the limited patient population.